Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL

Healthcare
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Cardiol Therapeutics Inc > Covid-19 traction coming
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(79)
•••
Comment by Youhillmanon Jul 18, 2020 9:37am
123 Views
Post# 31284641

RE:RE:RE:RE:RE:RE:Covid-19 traction coming

RE:RE:RE:RE:RE:RE:Covid-19 traction coming

Thank you vikingguy for the clarification!

Not sure why other companies and their products are listed on the Shoppers site as 'coming soon' yet they took CRDL off the website, I'm guessing its something to do with Health Canada.

I agree with you 100%, CRDL will surprise to the upside, this stock could go from its current price to $25 or so (similar to AXSM & MYOK), this would be due to approvals of Covid and Acute Myocarditis.

Also, If someone is looking for a pure CBD product, it will be the first one recommended by Shoppers regardless of the price.

I have no doubt this will be a billion dollar company in the next year.

By the way, the average cost per patient for Epidiolex is $32,000 a year, this works out to 12 cents per milligram, with the price falling in the middle of the CBD market.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities